LifeStance Health Group (LFST) closed the last trading session at $5.95, gaining 8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.63 indicates a 45% upside potential.The average comprises eight short-term price targets ranging from a low of $7 to a high of $10, with a standard deviation of $1.03. While the lowest estimate indicates an increase of 17.7% from the current price l ...

SCOTTSDALE, Ariz., May 28, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will present at the upcoming 46th Annual Goldman Sachs Healthcare Conference, which will be hosted in Miami, Florida. Details of the presentation are as follows:Presenters: Dave Bourdon, CEO, and Ryan McGroarty, CFODate: Tuesday, June 10, 2025 Time: 10:40 a.m. (Eastern time)Moderated by: Jamie Perse The prese ...

Core Insights - LifeStance Health has appointed Vaughn Paunovich as Chief Technology Officer, effective June 9, 2025, to lead the company's technology strategy and enhance the patient and clinician experience [1][2] - Paunovich has over 25 years of experience in healthcare technology, previously serving as EVP at Amwell and holding various leadership roles at UnitedHealth Group, including Chief Information Officer of Optum Health [2][3] - The transition follows the departure of Pablo Pantaleoni, who played a significant role in LifeStance's digital transformation since 2020 and will assist Paunovich during the transition [3] Company Overview - LifeStance Health, founded in 2017, is one of the largest providers of virtual and in-person outpatient mental healthcare in the U.S., operating over 550 centers across 33 states [4] - The company employs approximately 7,500 mental health professionals, including psychiatrists, psychologists, and therapists, with a mission to improve access to affordable and personalized mental healthcare [4]

Core Viewpoint - LifeStance Health Group (LFST) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly influenced by institutional investors [4][6]. - LifeStance Health is projected to earn -$0.10 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 33.3% [8]. - Over the past three months, the Zacks Consensus Estimate for LifeStance Health has increased by 31.6%, indicating a positive trend in earnings expectations [8]. Investment Implications - The upgrade to Zacks Rank 1 positions LifeStance Health in the top 5% of Zacks-covered stocks, suggesting potential for higher stock prices in the near term due to improved earnings outlook [10]. - Rising earnings estimates and the corresponding rating upgrade imply an enhancement in the company's underlying business, which should attract investor interest and drive the stock price higher [5][10].

LifeStance Health Group (LFST) has been on a downward spiral lately with significant selling pressure. After declining 20.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40478 LifeStance Health Group, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1832801 (State or other ju ...

Lifestance Health Group (LFST) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Monica Prokocki - Vice President, Investor RelationsDavid Bourdon - CEORyan McGroarty - CFOCraig Hettenbach - Executive DirectorRyan Daniels - Group Head–Healthcare Technology and ServicesRichard Close - Managing DirectorSteve Dechert - AVP Conference Call Participants Jamie Perse - Equity Research AnalystBrian Tanquilut - Equity Research Analyst - Healthcare Services Operator Good day everyone and thank you f ...

Lifestance Health Group (LFST) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Good day everyone and thank you for standing by. My name is Argy, and I will be your conference operator today. At this time, I would like to welcome everyone to LifeStan's Health first quarter twenty twenty five earnings call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask question during this time, sim ...

Group 1: Earnings Performance - LifeStance Health Group (LFST) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $332.97 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.08%, compared to year-ago revenues of $300.44 million [2] - Over the last four quarters, LifeStance Health has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - LifeStance Health shares have declined approximately 11.1% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.03 on revenues of $351.71 million, and -$0.10 on revenues of $1.42 billion for the current fiscal year [7] Group 3: Industry Context - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The favorable estimate revisions trend for LifeStance Health has resulted in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Reimagining Mental Health Q1 2025 Earnings Presentation • May 7, 2025 Forward-Looking Statements DISCLAIMERS Cautionary Note Regarding Forward-Looking Statements This presentation and related oral statements, including during any question and answer portion of the presentation, contain forward-looking statements about LifeStance Health Group, Inc. and its subsidiaries ("LifeStance") and the industry in which LifeStance operates, including statements regarding: full-year and second quarter guidance and manag ...